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  transplants. So far, this gold standard syn-
geneic control is of course missing in clini-
cal transplantation research although this 
might provide some keys in the understand-
ing of mechanisms involved in transplan-
tation tolerance. Perhaps, further clinical 
research  addressing  specific  biomarkers 
of tolerance should include experimental 
equivalent  of  the  syngeneic  transplants 
reported here as suggested by this nice study.
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Waldmann, 2010). If the success of experi-
mental protocols of tolerance induction or 
its maintenance depends on those mecha-
nisms, as   demonstrated by specific models, 
they do not represent a biomarker as such. 
This is well illustrated by the example that 
regulatory T cells have been found to be 
present in tolerated but also rejected allo-
grafts. Beyond the scope of alloreactivity, 
the mechanisms implicated in tolerance to 
self antigens are still incompletely under-
stood. Therefore, it looks tricky to define a 
promising strategy for identifying universal 
biomarkers of tolerance. Besides, the poten-
tial effects of immunosuppressive drugs on 
those tolerogenic mechanisms further com-
plicate the problem.
In the present issue, Cobbold et al. (2011)
chose an elegant and sophisticated experi-
mental alternative to overwhelm these dif-
ficulties (ref). They compared gene profile 
expression in draining lymph nodes, spleen, 
and transplanted tissue of three apparently 
different  immunological  situations:  skin 
allograft tolerance, skin allograft rejection, 
and syngeneic transplants. To ensure that 
observations were robust and unbiased, the 
allogeneic situation included transplanta-
tion across multiple minor antigen dispari-
ties, minor plus major (full mismatch) or in 
the presence of graft-reactive, monospecific 
TCR transgenic T cells. This confirmed that 
multiple innate and adaptive mechanisms 
are recruited in reliable forms of tolerance 
and operate within the graft, not system-
atically, strongly suggesting that fishing for 
surrogate markers of tolerance in patients 
should be performed with grafted tissue (or 
perhaps by-products) rather than PBMCs.
At least, two other important messages 
are  contained  in  this  manuscript.  First, 
foxp3 mRNA is definitely not a biomar-
ker of tolerance as such, and the fate of 
allograft depends on the balance between 
“regulatory-associated” genes and   effector 
genes. The second important message is that 
tolerated allografts behave like syngeneic 
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For obvious reasons, there is an urgent need 
to define reliable biomarkers of transplan-
tation tolerance that will allow better tai-
loring of immunosuppression and a safer 
withdrawal of immunosuppressive drugs. 
Simultaneously, this will make clinical tri-
als of tolerance induction easier to perform 
and promote. However, to date there is no 
reliable means to discriminate between the 
absence of rejection due to the effects of 
conventional  immunosuppression  and 
the absence of rejection due to the suc-
cessful induction of an active process of 
tolerance.  Consequently,  most  clinicians 
administer  a  classical  immunosuppres-
sive protocol to their patients or prefer to 
include patients in clinical trials driven by 
pharmaceutical companies.
The  problem  is  not  easy.  We  already 
know  from  basic  research  performed 
with peripheral blood mononuclear cells 
(PBMCs) from the rare patients that are 
“by chance” tolerant to a kidney allograft 
or the more frequent tolerant liver trans-
plant recipients, that putative biomarkers 
of  operational  tolerance  (that  remain  to 
be validated in large prospective studies) 
are  distinct  for  each  organ  (Martinez-
Llordella et al., 2008; Sagoo et al., 2010; 
Sanchez-Fueyo  and  Strom,  2011).  This 
suggests that the underlying mechanisms 
are distinct too. In experimental transplan-
tation models (small and large animals), 
the number of cells and the mechanisms 
involved in tolerance are numerous and are 
increasing (regulatory T cells, mast cells, 
myeloid derived suppressor cells, immune 
privilege,  enzyme  activity  such  as  iNOS, 
arginase,  heme    oxygenase-1,  NO,  etc…; 
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